Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. Although COVID-19 …

Emerging data indicate that neurological complications occur as a consequence of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The blood–brain barrier …

Amyloid beta peptide (Aβ) is produced through the proteolytic processing of a
transmembrane protein, amyloid precursor protein (APP), by β-and γ-secretases. Aβ …

Intracerebral hemorrhage associated with thrombolytic therapy with tissue plasminogen
activator (tPA) in acute ischemic stroke continues to present a major clinical problem. Here …

Rationale: Hemorrhagic complications represent a major limitation of intravenous
thrombolysis using tPA (tissue-type plasminogen activator) in patients with ischemic stroke …

Hemorrhagic transformation (HT) is a common complication of ischemic stroke that is
exacerbated by thrombolytic therapy. Methods to better prevent, predict, and treat HT are …

Disruptions of the blood–brain barrier (BBB) and edema formation both play key roles in the
development of neurological dysfunction in acute and chronic cerebral ischemia. Animal …

Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for …

The blood-brain barrier (BBB) is formed by the endothelial cells of cerebral microvessels,
providing a dynamic interface between the peripheral circulation and the central nervous …

The founding member of the lipoprotein receptor family, low-density lipoprotein receptor
(LDLR) plays a major role in the atherogenesis through the receptor-mediated endocytosis …